Difference between revisions of "Adenosquamous carcinoma of the lung"
Jump to navigation
Jump to search
(→Images) |
|||
| Line 43: | Line 43: | ||
#Adenocarcinoma component. | #Adenocarcinoma component. | ||
#Squamous cell carcinoma component. | #Squamous cell carcinoma component. | ||
DDx: | |||
*[[Squamous cell carcinoma of the lung]]. | |||
*[[Adenocarcinoma of the lung]]. | |||
===Images=== | ===Images=== | ||
Revision as of 05:35, 29 December 2015
| Adenosquamous carcinoma of the lung | |
|---|---|
| Diagnosis in short | |
 Adenosquamous carcinoma of lung. H&E stain. | |
| LM DDx | squamous cell carcinoma of the lung, adenocarcinoma of the lung |
| Site | lung - see lung tumours |
|
| |
| Prevalence | rare |
| Clin. DDx | other lung tumours |
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
Features:
- Adenocarcinoma component.
- Squamous cell carcinoma component.
DDx:
Images
ASC - intermed. mag. (WC)
ASC - intermed. mag. (WC)
ASC - high mag. (WC)
ASC - very high mag. (WC)
www
- Lung adenosquamous carcinoma (webpathology.com).
- Lung adenosquamous carcinoma (flickr.com/Yale Rosen).
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.